H

ello, everyone, and how are you today? We are doing just fine, thank you, now that another wintry storm has come and gone. A warm sun is now enveloping the Pharmalot campus, where the short person is leaving for the local schoolhouse and the officials mascots are enjoying diving about in the snow and slush. As for us, we are embarking on our usual daily journey of foraging for interesting items. And so, it is time to get cracking. Hope your day goes well and do drop us a line when something interesting develops …

Biosimilar versions of Roche’s (RHHBY) Rituxan blood cancer treatment have taken 80 percent of the U.K. market since launching last year, saving the health care system $113 million a year, Reuters writes. The rapid adoption of two biosimilars from Celltrion and Novartis has been accompanied by discounts of 50 percent to 60 percent as the U.K’s National Health Service has used bidding to bring down costs. The NHS has estimated that biosimilars could save it up to $420 million a year.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • May I observe that the last time Pfizer sold their Consumer Division, it was a great deal for J&J (the subsequent issues at Fort Washington not withstanding). Now it appears they will improve the lot of GSK. It seems Pfizer’s role is to enrich it’s competition – save the collateral damage to TEVA via Allergan, but “that’s just a coincidence.”

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.